Perfluorocarbons are prepared as liquids for injection into the intravascular or ventriculosubarachnoid spaces. To maintain circulating blood volume they can be readily mixed with a plasma volume expander such as dextran or hydroxyl starch. 32 However, because of their low water solubility, they first must be emulsified. The emulsifier, or surfactant, is a key component; it largely determines the properties of the emulsion, with the exception of the O 2 -carrying capacity which is determined by the fluorocarbon element. There are two major mechanisms underlying the efficacy of PFCs for O 2 transport and delivery. First, they have a high solubility coefficient for O 2 and CO 2 ; relative to hemoglobin, PFCs release O 2 into the surrounding tissue more effectively, because their O 2 -binding constant is negligible. 13, [29] [30] [31] [32] [33] 80 Second, the PFC particles are very small (most are less than 0.2 ). This facilitates their passage through capillaries and partially blocked vessels.
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First-Generation PFC Emulsions

Historical Review of Central Nervous System Protection by First-Generation PFCs
The ability of mammals to survive in fluorocarbon fluid equilibrated with O 2 at atmospheric pressure was first demonstrated by Clark and Golan in 1966. 13 In 1967, Sloviter and Kaminoto 102 reported the successful use of PFCs as erythrocyte substitutes in isolated rat brain preparations. In a series of studies conducted between 1968 and 1975, Geyrer 29-32 successfully replaced the entire blood volume of rats in vivo with a mixture containing emulsified perfluorotributylamine. These "bloodless rats" not only remained alive but also rapidly regenerated red cells and proteins after completion of the experiments. 29 A number of subsequent studies explored the effect of exchange transfusion with PFCs on neuronal activities. 40 In cats or rats, this technique satisfactorily maintained the reflexogenic control of respiration and circulation for more than three hours, 79 increased cerebral blood flow by 100%, 62 and maintained a higher mean arterial pressure and better metabolic cerebral function relative to controls.
ed Fluosol-DA as an intravenous cerebral protective agent in stroke models involving temporary ligation of cerebral arteries in cats or gerbils. Fluosol-DA improved tissue O 2 availability before the arterial ligation and during reperfusion 51 and reduced the infarct size 86 and the incidence of early hemiparesis. 52 However, 7 days later there was no reduction in overall morbidity, mortality, or size of the infarct. 51, 52 Oxygen delivery to the central nervous system (CNS) can also be enhanced by ventriculosubarachnoid perfusion using oxygenated PFCs. In cats subjected to cerebral arterial ligation together with severe hemorrhagic hypotension, ventriculosubarachnoid perfusion reestablished the abolished cerebral electrical activity and oxidative metabolism 85 and prevented large infarcts. 6,7 Using the pial window technique, Kontos, et al., 54 showed that cerebrospinal fluid perfusion with PFCs improved the local O 2 delivery and completely eliminated the reactive cerebral vasodilation induced by systemic hypoxia and hemorrhagic hypotension. Beneficial effects were also seen in experimental spinal ischemia in dogs. Intrathecal perfusion by oxygenated PFCs significantly improved motor recovery after acute spinal cord compression 41 and prevented paraplegia after aortic occlusion. 76 
Recent Progress in Myocardial Protection by FirstGeneration PFCs
Studies performed during the last 5 to 6 years have shown first-generation PFCs to be beneficial specifically in temporary myocardial ischemia followed by reperfusion. This finding invalidates early assumptions that PFCs may be detrimental in this setting because they could enhance the generation of O 2 -free radicals. In animal models of temporary coronary occlusion, reperfusion with Fluosol, 65, 91 particularly as a "white cell-free" perfusate, 53,99 significantly reduced myocardial infarct size. Models of microvascular injury attributed this beneficial effect not only to the O 2 -carrying capacity, but also to: 1) inhibition of neutrophil infiltration and plugging of capillaries in the reperfused region;
26 2) suppression of chemotaxis and lysozyme degranulation; 26 3) attenuation of neutrophil adherence, enzyme release, 2 and cytotoxicity to endothelial cell cultures; 2,27 and 4) preservation of endothelial structures and endothelium-dependent relaxation of large and small vessels.
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In humans, intravenous Fluosol offered a marginal antiischemic benefit during coronary balloon angioplasty. 119 However, local administration of Fluosol as an intracoronary infusion near the ischemic area attenuated myocardial ischemia, 49 alleviated chest pain, 3 and improved cardiac output and left ventricular ejection fraction. 17 In the light of this evidence, a 20% weight/volume Fluosol emulsion was approved in 1990 for human use as an adjunct to diminish myocardial ischemia during coronary angioplasty. 90 Another example, albeit isolated, of PFC application in humans was the successful use of Fluosol as a temporary blood substitute during a Whipple's pancreaticoduodenectomy in an anemic Jehovah's Witness. 
Second-Generation PFC Emulsions
The failure of first-generation PFCs to offer protection against persistent long-term ischemic insults has been attributed to a variety of factors, including a low fluorocarbon/emulsifier ratio, instability, short intravascular persistence (half-life), low PFC concentration in the circulation, and consequently a low O 2 -carrying capacity. 32, 93 Shortcomings associated with the emulsifying agent, PF68, were also identified. This agent affects polymorphonuclear leukocytes, 121 fibrin structure and fibrin-cell interactions, 11 increases viscosity, 47 inhibits cell growth, 60 and enhances superoxide anion production. 26 Particularly troublesome is its tendency to activate complement, 32, 117 with accompanying decreases in circulating white cell count, platelet count, 103 and O 2 tension. 32 As a result of these problems, it became apparent that the first-generation PFCs, in their original formulations, were not suitable for wide clinical application. However, since the late 1980s improvements in both fluorocarbon and emulsion technology have led to the development of significantly more biocompatible, stable, and efficient second-generation injectable O 2 carriers. The major advantage lies in their emulsifying component, egg-yolk phospholipids, which have been used as the primary surfactant for parenteral fat emulsions for many years. 87 Importantly, unlike PF68, these phospholipids do not activate complement and thus have no detrimental effect on the vascular system and on O 2 tension. 32 Certain refinements have resulted in greater overall emulsion stability and have led to increased persistence within the intravascular space. 114 A reduction in particle size has decreased viscosity and increased the rate of oxygen release into the local tissue. Higher PFC concentrations can now be achieved, by virtue of a greater fluorocarbon/emulsifier ratio relative to first-generation PFCs. For example, Perflubron (perfluorooctylbromide), a second-generation PFC, can be made in an emulsion nearly five times as concentrated as Fluosol.
5 Second-generation PFCs have been shown to inhibit platelet aggregation, 103 leukosequestration during periods of ischemia and reperfusion, 81 and endotoxin-mediated activation of endothelial cells. 59 They also delay O 2 desaturation and protect tissues from adenosine triphosphate depletion.
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The second-generation products are suitable in combination with autologous blood donation/transfusion and can be removed from the blood postoperatively by plasmapheresis-like methods.
5 Therefore, they seem to lend themselves to intraoperative use as hemodilutionary agents or during cardioplegia for complex neurosurgical procedures. The high PFC content of second-generation PFCs may reduce the absolute requirement for maintenance of a fraction of inspired O 2 at greater than 0.8 for optimal efficacy, as in the case of Fluosol, and pave the way for successful deployment in initial prehospital resuscitation of multiple-trauma patients suffering from hemorrhagic shock.
5,35
Potential Applications in Neurosurgery
Diagnostic Applications
Ultrasonography and Computerized Tomography. The PFCs containing a high concentration of 1-bromo-fluorooctane can be used as O 2 carriers and also as x-ray opaque material 63 and contrast agents in computerized tomography (CT). 9, 70, 71, 75 In addition, PFCs have sonographic properties; under certain conditions, they reflect ultrasound waves and create a clear real-time view of vascular flow and organ perfusion. 72 Intravenously administered perfluorooctylbromide improves imaging of veins and may aid delineation of venous thrombi on sonography. 16 High-resolution CT lymphography with PFCs may allow more accurate cancer detection in lymph nodes and better cancer staging. 123 Also, PFCs have given encouraging results as a medium for compartmental blood flow measurements in tumors. 21 Intravenous injection of perfluorooctylbromide enhances CT images of liver abscesses in rabbits. 73 However, one must consider the potential risks of this agent when used in such a capacity; current preparations may interfere with the reticuloendothelial system and could compromise the immune response.
Magnetic Resonance Imaging and Spectroscopy. Perfluorocarbons may prove particularly helpful in functional neuroimaging using magnetic resonance (MR) imaging. 24 74 The presence of the F atom in the perfluorooctylbromide molecule renders it a unique MR imaging agent for blood-pool applications in solid organs. 70 Magnetic resonance imaging of PFCs can also be used to determine tissue O 2 levels. Spin-lattice relaxation times of PFC emulsions are oxygen sensitive. This allows determination of mean vascular PO 2 independent of the blood volume in the tissue. This property of PFCs has been used to determine the oxygen tension in blood 25 or its regional variations in the rat liver, spleen, 25 and reticuloendothelial system. 46 Oxygen tension maps have been computed from 19 F MR imaging for Fluosol in vitro. 46 Another use for PFCs could involve MR spectroscopy, 105 which can accurately quantify PFCs in tissues 88 and assess blood volume. 112 Magnetic resonance spectroscopy of 19 F is sensitive to tissue PO 2 . This allows measurement of tissue oxygenation, 68, 118 tumor PO 2 in vivo, 112 or formation of O 2 maps of the brain. 118 Oxygen tension measurements have been obtained by analyzing the perfluorooctylbromide 19 F spectrum signal perturbation by the paramagnetic molecule. 112, 122 In addition, the significant temperature dependence of the F chemical shift permits simultaneous in vivo determination of O 2 tension and tissue temperature.
4,69
Therapeutic Applications Cerebral Protection. As discussed above, PFCs appear to be most promising as temporary antiischemic agents in a localized ischemic zone if administered immediately after the insult. They have been shown to alleviate myocardial ischemia in humans by perfusion distal to the balloon during coronary balloon angioplasty.
3,17,26,27,49,119 It is possible, therefore, that they may be useful in situations in which cerebral ischemia is expected or likely to be induced with treatment, such as during temporary clipping of proximal arteries before clipping of aneurysms, or intravascular embolization procedures. Recently, use of fluoromethyladamantane, a second-generation PFC, resulted in a 61% decrease in cerebral infarct size in rabbits subjected to intracranial arterial ligation, compared to the control animals which were treated with normal saline. 98 A more extensive study of isovolemic hemodilution with fluoromethyladamantane confirmed this finding and demonstrated a benefit comparable to that of dextran. 97 In other experiments, second-generation PFCs have improved tissue oxygenation in cat retina 8 or improved the circulating O 2 tension by more than 50% relative to their first-generation counterparts.
32 Until now, the success of PFCs in clinical trials for antiischemic protection has been hindered by legislation limiting the concentration of firstgeneration PFCs permissible in humans to 2% to 4%, which is too low a level to demonstrate efficacy under many clinical conditions. 32 Concentrations of second-generation PFC emulsions could be safely increased by virtue of their failure to activate complement. Lower inspired O 2 levels of 60% may then be sufficient to achieve a higher O 2 circulating tension and therapeutic levels in tissue.
Treatment of Malignant Tumors. It is possible that the O 2 -carrying capacity of PFCs could be exploited in conjunction with radiation therapy and chemotherapeutic agents for the treatment of tumors containing cells that thrive in hypoxic conditions. Many anticancer drugs require O 2 to be cytotoxic or are selectively cytotoxic toward cells under oxygenated conditions. [108] [109] [110] [111] In rats with rhabdomyosarcoma, pretreatment with PFCs augments changes induced by inhalation of 100% O 2 such as hemoglobin saturation, cytochrome oxidation, tumor PO 2 , and radiosensitivity. 104 In experimental animals, perfluorooctylbromide increased radiosensitivity of solid mammary tumors or rhabdomyosarcomas relative to normal tissues. 83, [94] [95] [96] Perfluorooctylbromide combined with CO 2 inhalation increased the radiosensitivity of fibrosarcomas to low levels of radiation 107 and the efficacy of chemotherapeutic agents, 45 without a concomitant increase in bone marrow toxicity. 111 Perfluoro-N-methyldecahydroisoquinoline, another second-generation PFC emulsion, provided similarly encouraging results. 94 Perfluorooctylbromide has also been used to increase the radiosensitivity of human tumor xenografts. 39 However, the only PFC that has been tested in humans is Fluosol; it was well tolerated as an adjunct to primary radiation in patients with advanced head and neck malignancies, 10,64 anaplastic astrocytomas, and glioblastomas multiforme.
20,22 A study of 20 patients with anaplastic astrocytoma or glioblastomas multiforme who were treated with Fluosol, hyperbaric O 2 , and radiotherapy demonstrated that Fluosol can be safely used in such patients. 20 In another study, the results indicated that the addition of Fluosol to conventional radiotherapy does not enhance survival of any patients but does improve the quality of life of patients who survive past the 1st year. The minimal side effects suggest that Fluosol/O 2 sensitizes only hypoxic cells, with no effect on well-oxygenated normal brain tissue.
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Other potential applications of PFCs include cancer staging and monitoring of tumor response to treatment. The latter may involve noninvasive measurement and monitoring of regional tumor O 2 levels and vascularity.
12,24,42,66 Given the critical role of O 2 tension in tumor response to therapy, this may provide new insight into tumor physiology, the efficacy of various therapeutic approaches, and ultimately provide a clinical technique for assessing individual tumor oxygenation. 66 
Transplantation and Preservation of Isolated Organs.
Surface fluorometry and electrical activity monitoring of the isolated rat brain suggest that viability of the isolated CNS tissue can be maintained by perfusion with a PFC blood substitute. 77, 102 Perfluorocarbons have been used to similar effect in other organs. 101 Their use in the form of acellular O 2 -carrying perfusates resulted in extended in vivo preservation of an autoperfused working heart-lung preparation.
48 Several other studies have suggested that PFC emulsions may have a role in the preservation of ischemically damaged isolated organs 57, 58, 82 or organs that are intended for transplantation.
50,56
Management of Air Embolism. The solvent action of PFC emulsions on gases raises the possibility that these compounds may have a protective role in the management of air embolism. 78 On introducing air bubbles into the carotid artery of rats, it was found that PFC-treated animals tolerated greater numbers of air emboli and maintained significantly higher levels of blood PO 2 compared to controls.
78,106
Ventilatory Support. Liquid ventilation by PFCs may prove to be an effective means of optimizing oxygen delivery and blood-gas exchange. In preterm animals, it gave superior results compared to gas ventilation in terms of clinical, physiological, and histological correlates and mortality rate. 124 It may be beneficial in head-injured patients with compromised pulmonary function because of neurogenic pulmonary edema, aspiration, 84 or acute respiratory distress syndrome (ARDS). 115, 116 Liquid ventilation using PFCs eliminates surface tension, due to pulmonary air-fluid interfaces, and improves pulmonary function.
28, 61 In lung-injured experimental animals, PFC liquid lung lavage removed pulmonary edema fluid, improved gas exchange and the mechanical properties of the lung, 92 and reduced lung damage. 43 Intratracheal PFCs reduced airway pressure and increased respiratory system compliance without a change in cardiovascular status; 18 this type of ventilatory support, therefore, may become an effective alternative treatment of ARDS. 43, 44 Clinical trials in human preterm neonates demonstrated the feasibility of liquid ventilation using PFCs, improving oxygenation in two of three infants; this was associated with a marked improvement in lung distensibility without a change in cardiovascular status. 37 However, documentation of safety is necessary before this modality assumes a wide role in clinical practice.
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Microsurgery. The lack of significant toxicity of PFCs against the human CNS has been documented by their use in vitreoretinal microsurgery. Because of their high viscosity, PFCs are now used as an intraocular tool at the interface between retina and vitreous body, for the exact anatomical reapposition of giant retinal tears, 55 complicated retinal detachments, 19 and to mobilize and separate vitreous hemorrhage, partially detached posterior hyaloid membrane, or subluxated lenses from the retina.
38,100,120 Increased awareness by neurosurgeons of the use of PFCs in this capacity may lead to future use of these compounds in a similar role in microneurosurgery.
Future PFC Emulsions
Emulsions of PFCs are remarkably biocompatible. The absence of substantial toxicity has been fully recognized.
Their O 2 -carrying capacity has been increased since their introduction and their efficacy in temporarily alleviating localized ischemia has been confirmed. The second-generation products seem to lend themselves to intraoperative use. Their application in the radiation and chemotherapy of malignant diseases and in diagnostic imaging holds significant promise. However, the retention of PFCs in the intravascular space is still too brief for blood substitute applications or for protection against prolonged ischemic insults. To overcome these problems, future developments are likely to depend largely on refinement of their surfactant component. Advances should provide: 1) improved stability and long-term storage; 2) greater capacity for altering emulsion properties according to specific investigative or therapeutic indications; 3) improved PFC purity; 4) ability to prevent or modulate the biological response triggered in the body by the surfactant-coated particles; and 5) improved intravascular persistence and organ or tissue distribution. 
